Kalaris Therapeutics (NASDAQ:KLRS) Raised to Hold at Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Monday, Wall Street Zen reports.

Separately, Weiss Ratings raised Kalaris Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.75.

View Our Latest Stock Analysis on KLRS

Kalaris Therapeutics Price Performance

NASDAQ:KLRS opened at $1.43 on Monday. The firm has a 50 day simple moving average of $2.45 and a 200-day simple moving average of $4.99. Kalaris Therapeutics has a 1-year low of $1.33 and a 1-year high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06. As a group, research analysts expect that Kalaris Therapeutics will post -1.92 EPS for the current year.

Hedge Funds Weigh In On Kalaris Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. boosted its holdings in shares of Kalaris Therapeutics by 146.8% in the 3rd quarter. Goldman Sachs Group Inc. now owns 39,616 shares of the company’s stock valued at $114,000 after purchasing an additional 23,562 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Kalaris Therapeutics during the 3rd quarter valued at $65,000. Pale Fire Capital SE acquired a new stake in shares of Kalaris Therapeutics during the 2nd quarter worth $161,000. Sigma Planning Corp acquired a new stake in shares of Kalaris Therapeutics during the 2nd quarter worth $41,000. Finally, BlackRock Inc. acquired a new stake in shares of Kalaris Therapeutics during the 2nd quarter worth $222,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Kalaris Therapeutics

(Get Free Report)

Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. Its work centers on advancing investigational therapies intended to address conditions affecting vision. The company’s product candidates are in development and are not approved for commercial use. Kalaris’s activities include research and development and the clinical evaluation of potential therapies. Publicly available information about the company’s leadership and geographic operations is limited.

See Also

Analyst Recommendations for Kalaris Therapeutics (NASDAQ:KLRS)

Receive News & Ratings for Kalaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.